The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 08, 2019

Filed:

Jan. 22, 2016
Applicant:

Tella, Inc., Tokyo, JP;

Inventor:

Takashi Nishimura, Sapporo, JP;

Assignee:

Tella, Inc., Tokyo, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C07K 14/47 (2006.01); C12N 5/0783 (2010.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0011 (2013.01); C07K 14/4747 (2013.01); C07K 14/4748 (2013.01); C12N 5/0636 (2013.01); A61K 38/00 (2013.01); A61K 39/00 (2013.01); C12N 2501/998 (2013.01);
Abstract

The object aims to provide: a novel tumor antigen; a novel therapeutic agent useful in a method for treating a malignant neoplasm by utilizing the tumor antigen; and a tumor antigen which can be used as the therapeutic agent. Thus, disclosed are: a novel tumor antigen which has an epitope capable of inducing a Th1 cell which is a CD4-positive T cell specific to Survivin; and use of the tumor antigen. Specifically disclosed is a polypeptide which comprises an amino acid sequence depicted in SEQ ID NO:17 or the like and has an activity to cause the production of a cytokine by a Th cell that is a cell specific to Survivin. The peptide can induce a Th cell that is specific to Survivin and can cause the production of a cytokine by the Sur/Th cell when the peptide is incubated together with an antigen-presenting cell and a CD4-positive T cell.


Find Patent Forward Citations

Loading…